Given that transcriptional changes associated with the acquisition of MYC amplification in setting of immunotherapeutic resistance is poorly understood in HNSCC, we next performed RNA-Seq analysis of the tumor specimens collected from the patient described in the case report at baseline and upon rapid progression of R/M disease while receiving nivolumab (Supplementary Data 2). The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.